Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Kybella With Triamcinolone

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03361176
Recruitment Status : Recruiting
First Posted : December 4, 2017
Last Update Posted : December 20, 2017
Sponsor:
Collaborators:
Allergan
Maryland Laser Skin and Vein Institute
Information provided by (Responsible Party):
Goldman, Butterwick, Fitzpatrick and Groff

Brief Summary:
This study is to evaluate the efficacy, edema and pain associated with Kybella(TM) injections of the upper neck in the treatment of submental fat with varying low concentrations of triamcinolone acetonide plus low doses of lidocaine.

Condition or disease Intervention/treatment Phase
Adiposity Drug: Injectable sodium deoxycholate Combination Product: Injectable sodium deoxycholate with Triamcinolone acetate Phase 4

Detailed Description:

This is a two-site randomized, double-blind comparison trial of Kybella(TM) injections with or without triamcinolone acetate for the reduction of submental fat. 30 subjects will be enrolled into the trial (15 subjects per site). At each site, 5 will be randomized to receive Kybella(TM) injections alone whereas 10 will receive Kybella(TM) plus differing doses of triamcinolone acetate in the following way:

  1. Group 1 (5 patients per site): Kybella(TM) alone: 2 mg/cm2 of Kybella(TM) with 0.2 mL of 1% lidocaine with no epinephrine plus 0.2cc saline to the non-TMC group to maintain equal concentrations in each injection so that the final Kybella concentration per vial will be 10mg/1.2mls or 1.6mg per 0.2 cc injection point will be delivered in up to 50 injections spaced 1.0 cm apart at 0.2 mL/injection for a total maximal dose of up to 100 mg of SDOC.
  2. Group 2 (10 patients per site): Kybella(TM)+TMC at 1.0 mg/mL: 2.0 mL of 2 mg/cm2 of Kybella(TM) will be mixed with 0.2 mL of 10 mg/mL of triamcinolone acetate, 0.2 mL of 1% lidocaine with no epinephrine and then delivered in up to 50 injections spaced 1.0 cm apart at 0.2 mL/injection for a total dose of up to 100 mg of SDOC using a 30 gauge (or smaller) 0.5-inch needle. The final Kybella concentration per vial will be 10mg/1.2mls or 1.6mg per 0.2 cc injection point

The treatment area will be bounded superiorly by a line 1 cm inferior to the mandibular margin, laterally by the sternocleidomastoid muscles, and inferiorly by the hyoid bone. The subjects and evaluating investigator will be blinded to the treatment, thus maintaining double-blind status. By nature of the varying volumes of injection, the treating investigator will be unblinded to the treatment. A series of 3 injection sessions will be performed spaced 4 weeks apart. No lidocaine will be injected prior to injections to prevent further dilution of injected Kybella™ as it will be premixed with Kybella™. Chilling with cold will be the method of pain reduction for needle insertion.

Canfield Vectra 3D imaging will be performed at baseline and final visit (Appendix C) with analysis and calculation of volumetric changes performed at baseline and final visit. Photos will also be taken with the Intellistudio at all other visits. Follow up visits will be performed 3 and 5 days after each injection session to assess for side effect and tolerability profile. After the final injection session, additional follow up visits will be performed at days 90 and 180 to assess for efficacy. Subject weight will be recorded at baseline and at end of study.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: 10 subjects will be part of a control group treated without triamcinolone and 20 subjects will be treated with triamcinolone.
Masking: Double (Participant, Outcomes Assessor)
Masking Description: Participants and Outcomes Assessors will be blinded to the treatment arms subjects are randomized to.
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Dose-ranging Trial of Subcutaneous Sodium Deoxycholate Injections With or Without Low Dose Triamcinolone and Low Dose Lidocaine for Reduction of Submental Fat With Reduction of Pain and Swelling
Estimated Study Start Date : December 2017
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : March 2019


Arm Intervention/treatment
Active Comparator: Control
Control Group (5 patients per site): Kybella(TM) alone: 2 mg/cm2 of Kybella(TM) with 0.2 mL of 1% lidocaine with no epinephrine plus 0.2cc saline delivered in up to 50 injections per treatment session.
Drug: Injectable sodium deoxycholate
Kybella(TM) alone: 2 mg/cm2 of Kybella(TM) with 0.2 mL of 1% lidocaine with no epinephrine plus 0.2cc saline to the non-TMC group to maintain equal concentrations in each injection so that the final Kybella concentration per vial will be 10mg/1.2mls or 1.6mg per 0.2 cc injection point will be delivered in up to 50 injections spaced 1.0 cm apart at 0.2 mL/injection for a total maximal dose of up to 100 mg of SDOC.
Other Name: Kybella

Experimental: w/ Triamcinolone
Experimental Group (10 patients per site): Kybella(TM)+TMC at 1.0 mg/mL: 2.0 mL of 2 mg/cm2 of Kybella(TM) will be mixed with 0.2 mL of 10 mg/mL of triamcinolone acetate and 0.2 mL of 1% lidocaine with no epinephrine delivered in up to 50 injections per treatment session.
Combination Product: Injectable sodium deoxycholate with Triamcinolone acetate
Kybella(TM)+TMC at 1.0 mg/mL: 2.0 mL of 2 mg/cm2 of Kybella(TM) will be mixed with 0.2 mL of 10 mg/mL of triamcinolone acetate, 0.2 mL of 1% lidocaine with no epinephrine and then delivered in up to 50 injections spaced 1.0 cm apart at 0.2 mL/injection for a total dose of up to 100 mg of SDOC using a 30 gauge (or smaller) 0.5-inch needle. The final Kybella concentration per vial will be 10mg/1.2mls or 1.6mg per 0.2 cc injection point
Other Name: Kybella with Triamcinolone Acetate




Primary Outcome Measures :
  1. Change in Clinician-Reported Submental Fat Rating Scale [ Time Frame: 180 Days from Baseline ]
    Change in efficacy will be measured from Baseline to 180 days post final treatment using a 5-point Clinician-Reported Submental Fat Rating Scale ranging from Absent to Extreme submental convexity.


Secondary Outcome Measures :
  1. Difference in post-treatment Edema between subjects treated with and without Triamcinolone [ Time Frame: Post-treatment to Day 180 ]
    Edema will be compared between treatment groups at each post-treatment time point through Day 180 using a 5-Point Clinician Evaluation of Side Effects Scale ranging from None to Severe.

  2. Difference in post-treatment Pain between subjects treated with and without Triamcinolone [ Time Frame: Post-treatment to Day 180 ]
    Pain will be compared between treatment groups at each post-treatment time point through Day 180 using a 5-Point Subject Evaluation of Side Effects Scale ranging from None to Severe.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Females or Males in good general health age 18 - 65 years of age
  2. Fitzpatrick skin types I-VI
  3. Must be willing to give and sign a HIPAA form and informed consent form
  4. Must be willing and able to comply with all study protocols and schedules
  5. Must have submental fat graded by the investigator as 2 or 3 using the Clinician-Reported Submental Fat Rating Scale (PR-SMFRS)
  6. Negative urine pregnancy test prior to each treatment (if applicable)
  7. Female patients will be either of non-childbearing potential defined as:

    7.1 Having no uterus 7.2 No menses for at least 12 months. Or; (WOCBP) women of childbearing potential must agree to use an effective method of birth control during the course of the study, such as: 7.3 Oral contraceptive pill, injection, implant, patch, vaginal ring, intrauterine device 7.4 Intrauterine coil 7.5 Bilateral tubal ligation 7.6 Barrier method used with an additional form of contraception (e.g., sponge, spermicide or condom) 7.7 Abstinence (If practicing abstinence must agree to use barrier method described above (7.6) if becomes sexually active) 7.8 Vasectomized partner (must agree to use barrier method described above (7.6) if becomes sexually active with unvasectomized partner)

  8. Males must be willing to be clean shaven for all study visits
  9. The patient must have had a stable weight (no fluctuation of >15 pounds in a year), diet, and physical activity for the previous 6 months

Exclusion Criteria:

  1. Pregnancy, currently breast feeding or planning pregnancy for the duration of the trial
  2. Any UNCONTROLLED systemic disease -a potential patient in whom therapy for a systemic disease is not yet stabilized will not be considered for entry into the study
  3. Treatment with botulinum toxin injections in the neck or chin area within 6 months before randomization
  4. Any Scars, unshaven hair, tattoos or jewelry on or near the proposed treatment area
  5. Significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study
  6. An active dermatitis or open wound in the proposed treatment area
  7. An active bacterial, fungal, or viral infection in the proposed treatment area
  8. Pre-existing skin condition to the submental region that may confound evaluation or analysis, at investigator discretion
  9. Previously treated with subcutaneous sodium deoxycholate to the submental region
  10. Previously treated with focused ultrasound, radiofrequency, cryolipolysis or liposuction to the submental region within the previous 6 months
  11. Any other laser, light energy device, or chemical peel treatment to the submental region within the previous 3 months
  12. Pre-existing neurological or gastrointestinal condition leading to dysphagia, dysphonia or facial nerve palsy
  13. Pre-existing medical condition other than increased submental fat that may result in increased submental fullness such as but not limited to thyroid enlargement, goiter, cervical lymphadenopathy etc., at investigator discretion
  14. Must not have a planned fat reduction procedure of any variety to the submental region for the duration of the study
  15. Must not have planned significant alterations in diet or physical activity that may result in significant fluctuations in weight
  16. Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03361176


Contacts
Layout table for location contacts
Contact: Christi Myers (410) 666-3960 CMyers@MDLSV.com

Locations
Layout table for location information
United States, California
West Dermatology Research Center Not yet recruiting
San Diego, California, United States, 92121
Contact: Kristi Cobb    858-657-1004 ext 139    KCobb@CLDerm.com   
Contact: Isabella Guiha    858 657 1004 ext 119    IGuiha@CLDerm.com   
Principal Investigator: Mitchel P Goldman, MD         
United States, Maryland
Maryland Dermatology Laser, Skin and Vein Institute Recruiting
Hunt Valley, Maryland, United States, 21030
Contact: Christi Myers       CMyers@MDLSV.com   
Principal Investigator: Robert Weiss, MD         
Sponsors and Collaborators
Goldman, Butterwick, Fitzpatrick and Groff
Allergan
Maryland Laser Skin and Vein Institute

Layout table for additonal information
Responsible Party: Goldman, Butterwick, Fitzpatrick and Groff
ClinicalTrials.gov Identifier: NCT03361176     History of Changes
Other Study ID Numbers: Kybelladose-2017-02
First Posted: December 4, 2017    Key Record Dates
Last Update Posted: December 20, 2017
Last Verified: December 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Additional relevant MeSH terms:
Layout table for MeSH terms
Triamcinolone
Triamcinolone Acetonide
Triamcinolone hexacetonide
Triamcinolone diacetate
Lidocaine
Epinephrine
Racepinephrine
Epinephryl borate
Deoxycholic Acid
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Anti-Arrhythmia Agents
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Adrenergic beta-Agonists
Bronchodilator Agents
Autonomic Agents
Anti-Asthmatic Agents
Respiratory System Agents
Mydriatics